A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Radiotherapy is used in the treatment of approximately 50% of all malignancies including
gastrointestinal cancers. Radiation can be given prior to surgery (neoadjuvant radiotherapy) …

In eukaryotic cells, maintenance of genomic stability relies on the coordinated action of a
network of cellular processes, including DNA replication, DNA repair, cell-cycle progression …

In order to maintain genomic stability, cells have developed sophisticated signalling
pathways to enable DNA damage or DNA replication stress to be resolved. Key mediators of …

The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …

Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one
approach to the development of targeted cancer therapies. Mutations in ARID1A represent …

The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells.
DDR deficiencies can promote tumorigenesis but concurrently may increase dependence …

Oxygen deprivation (hypoxia) in non–small cell lung cancer (NSCLC) is an important factor
in treatment resistance and poor survival. Hypoxia is an attractive therapeutic target …

Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic
ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test …

Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that
shows great promise for tumour selectivity. Key components of the DDR are the ataxia …